Recent News

December 16, 2024

Sydnexis Featured in Review of Myopia Management

Perry Sternberg, Chief Executive Officer of Sydnexis interviewed by Review of Myopia Management.
View Source

Privately held, clinical-stage pharmaceutical company, Sydnexis Inc. has recently completed an evaluation of its patented low-dose atropine formulation, SYD-101, in a Pivotal Phase 3 clinical trial. Based in San Diego and founded in 2014, Sydnexis recently named Perry J. Sternberg Chief Executive Officer. Dwight Akerman, OD, MBA, Chief Medical Editor of Review of Myopia Management, interviewed Perry Sternberg to learn more about the company and its therapeutic focus on the clinical development of ophthalmic treatments for disease states with limited treatment options.

Sydnexis may use and disclose online usage data about you collected automatically through online tracking technologies such as cookies, pixels, and web beacons (collectively, "cookies"). We use this data for multiple purposes, including for online targeted advertising (advertisements based on your interests inferred from your activity across other unaffiliated sites and services) and website analytics purposes, as well as to personalize content, save your preferences, provide social media features, and track the site’s performance, as further described in the "Cookies and similar tracking and data collection technologies" section of our Privacy Notice. We retain this data for as long as necessary to fulfill these purposes or as needed to comply with our record retention obligations. We do not sell your data, but we may disclose it to our marketing and advertising partners for purposes of online targeted advertising or for website analytics purposes. To opt out of the use or disclosure of your cookie-based personal data for online targeted advertising or for website analytics purposes, or to otherwise manage your preferences, please click on Cookie Settings below. For additional information on the categories of data we collect, the purposes for their collection, disclosures to third parties, and data retention, please visit our Privacy Notice.